Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NMDA Modulation in Major Depressive Disorder
NCT04637620Phase 2Recruiting
- Sponsor
- China Medical University Hospital
- Start
- Jun 2017
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sodium benzoate in major depressive disorder (MDD), sponsored by China Medical University Hospital. Started Jun 2017; status: recruiting.
02
Drugs
sodium benzoate
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04637620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04637620.